Clinical evidence of the relationship between aspirin and breast cancer risk (Review)
- Authors:
- Nadia J. Jacobo-Herrera
- Carlos Pérez-Plasencia
- Elizabeth Camacho‑Zavala
- Gabriela Figueroa González
- Eduardo López Urrutia
- Verónica García‑Castillo
- Alejandro Zentella-Dehesa
-
Affiliations: Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición ‘Salvador Zubirán’, Tlalpan 14000, Mexico, D.F., Mexico , Unidad de Biomedicina FES-Iztacala, Universidad Nacional Autónoma de México UNAM, Tlalnepantla 54090, Mexico, Laboratorio de Oncogenómica, Instituto Nacional de Cancerología, Tlalpan 14080, Mexico, D.F., Mexico - Published online on: June 13, 2014 https://doi.org/10.3892/or.2014.3270
- Pages: 451-451
This article is mentioned in:
Abstract
 |
|
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chávarri-Guerra Y, Villarreal-Garza C, Liedke PE, et al: Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol. 13:e335–e343. 2012.PubMed/NCBI | |
|
Rodríguez-Cuevas SA and Capurso-García M: Epidemiology of breast cancer. Ginecol Obstet Mex. 74:585–593. 2006.(In Spanish). | |
|
Zentella-Dehesa A, Frías S, Galicia-Vázquez G, et al: Cáncer de glándula mamaria y metástasis: un creciente problema de salud pública en México. Mensaje Bioquímico. Oria Hernández J, Rendón Huerta E, Reyes Vivas H, Romero Álvarez I and Velázquez López I: Mexico: UNAM; XXXI. pp. 172–195. 2007 | |
|
Spallarossa P, Altieri P, Aloi C, et al: Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. Am J Physiol Heart Circ Physiol. 297:H2169–H2181. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Elliott P: Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol. 33:S2–S7. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rice J: Metastasis: The rude awakening. Nature. 485:S55–S57. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Khuder SA and Mutgi AB: Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 84:1188–1192. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Agrawal A and Fentiman IS: NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract. 62:444–449. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson TW, Anderson KE, Lazovich D and Folsom AR: Association of aspirin and nonsteroidal anti-inflammatory drugs use with breast cancer. Cancer Epidemiol Biomarkers Prev. 11:1586–1592. 2002.PubMed/NCBI | |
|
Harris RE, Chlebowski RT, Jackson RD, et al: Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res. 63:6096–6101. 2003. | |
|
Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR and Hawk E: Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 24:3177–3184. 2004.PubMed/NCBI | |
|
Marshall SF, Bernstein L, Anton-Culver H, et al: Nonsteroidal anti-inflammatory drugs use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 97:805–812. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Egan KM, Stampfer MJ, Giovannucci E, Rosner BA and Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 88:988–993. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kirsh VA, Kreiger N, Cotterchio M, Sloan M and Theis B: Nonsteroidal anti-inflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol. 166:709–716. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Terry MB, Gammon MD, Zhang FF, et al: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 291:2433–2440. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Coogan PF, Palmer JR, Strom BL and Rosenberg L: Use of nonsteroidal anti-inflammatory drugs and risk of breast cancer: the case-control surveillance study revisited. Am J Epidemiol. 162:165–170. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ and Olsen JH: A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 88:684–688. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Friis S, Thomassen L, Sørensen HT, et al: Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev. 17:88–96. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cook NR, Lee IM, Gaziano JM, et al: Low-dose aspirin in the primary prevention of cancer. The Women’s Health Study: a randomized controlled trial. JAMA. 294:47–55. 2005. | |
|
Jacobs EJ, Thun MJ, Connell CJ, et al: Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidem Biomarkers Prev. 14:261–264. 2005.PubMed/NCBI | |
|
Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ and Calle EE: A large cohort study of long-term daily use of adult strength aspirin and cancer incidence. J Nat Cancer Inst. 99:608–615. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schreinemachers DM and Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5:138–146. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Bardia A, Ebbert JO, Vierkant RB, et al: Association of aspirin and non-aspirin non-steroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 99:881–889. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Badawi AF, Habib SL, Mohammed MA, Abadi AA and Michael MS: Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest. 20:651–656. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Martey CA, Pollock SJ, Turner CK, et al: Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblast: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol. 287:L981–L991. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ready A, Velicer CM, McTiernan A and White E: NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 109:533–543. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE and Kolonel LN: Nonsteroidal anti-inflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemol. 166:1150–1158. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Langman MJS, Cheng KK, Gilman EA and Lancashire RJ: Effect of anti-inflammatory drugs overall risk of common cancer: case-control study in general practice research database. BMJ. 320:1642–1646. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Moorman PG, Grubber JM, Millikan RC and Newman B: Association between nonsteroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control. 14:915–922. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cotterchio M, Kreiger N, Sloan M and Steingart A: Nonsteroidal anti-inflammatory drug used and breast cancer risk. Cancer Epidemiol Biormarkers Prev. 10:1213–1217. 2001.PubMed/NCBI | |
|
García Rodríguez LA and González Pérez A: Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 91:525–529. 2004.PubMed/NCBI | |
|
Swede H, Mirand AL, Menezes RJ and Moysich KB: Association of regular aspirin use and breast cancer risk. Oncology. 68:40–47. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Slattery ML, Curtin K, Baumgartner R, et al: IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev. 16:747–755. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hojo T, Akiyama Y, Nagasaki K, et al: Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett. 171:103–110. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Maass N, Hojo T, Rosel F, Ikeda T, Jonat W and Nagasaki K: Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin Biochem. 34:303–307. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Girish GV, Sinha N, Chakraborty K, Bhattacharya G, Kahn NN and Sinha AK: Restoration by aspirin of impaired plasma maspin level in human breast cancer. Acta Oncol. 45:184–187. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bhattacharyya M, Girish GV, Ghosh R, Chakraborty S and Sinha AK: Acetylsalicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients. Cancer Sci. 101:2105–2109. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 379:1592–1601. 2012.PubMed/NCBI | |
|
Bambace NM and Holmes CE: The platelet contribution to cancer progression. J Thromb Haemostat. 9:237–249. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nature Rev Cancer. 9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gay LJ and Felding-Habermann B: Contribution of platelets to tumour metastasis. Nature Rev Cancer. 11:123–134. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Holmes MD, Chen WY, Li L, Hetzmark E, Spiegelman D and Hankinson SE: Aspirin intake and survival after breast cancer. J Clin Oncol. 28:1467–1472. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Smith WL, DeWitt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 69:145–182. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 215:1–20. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Giercksky KE: COX-2 inhibition and prevention of cancer. Best Pract Res Clin Gastroenterol. 15:821–833. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ulrich CM, Bigler J and Potter JD: Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Review Cancer. 6:130–140. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Moran EM: Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risk. J Environ Pathol Toxicol Oncol. 21:193–202. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Vane JR and Botting RM: Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum. 26:2–10. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Buttar NS and Wang KK: The “aspirin” of the new millenium: cyclooxigenase-2 inhibitors. Mayo Clin Proc. 75:1027–1038. 2000. | |
|
Elwood PC, Gallagher AM, Duthie GG, Mur LA and Morgan G: Aspirin, salicylates, and cancer. Lancet. 373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK and Venning G: Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 105:1107–1113. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O and Spano JP: Cyclooygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol. 59:51–64. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 90:455–460. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
He TC, Chan TA, Volgestein B and Kinzlet KW: PPAR delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 99:335–345. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Davies G, Martin LA, Sacks N and Dowsett M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 13:669–678. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Subbaramaiah K, Chung WJ and Dannenberg AJ: Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem. 273:32943–32949. 1998. View Article : Google Scholar | |
|
Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE and Robertson FM: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 140:27–35. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early breast cancer. N Engl J Med. 349:1793–1802. 2003.PubMed/NCBI | |
|
Mazhar E, Ang R and Waxman J: COX inhibitors and breast cancer. Br J Cancer. 94:346–350. 2006. View Article : Google Scholar | |
|
Bosetti C, Gallus S and La Vecchia C: Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 17:871–888. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Crew KD and Neugut AI: Aspirin and NSAIDs: effects in breast and ovarian cancers. Curr Opin Obstet Gynecol. 18:71–75. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 30:3–21. 2000.PubMed/NCBI | |
|
Bosetti C, Gallus S and La Vecchia C: Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev. 11:535–542. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Howe LR, Subbaramaiah K, Brown AMC and Dannenberg AJ: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 8:97–114. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ratnasinghe D, Daschner PJ, Anver MR, et al: Cyclooxygenase-2 P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res. 21:2141–2147. 2001.PubMed/NCBI | |
|
Streuli CH: Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo. Breast Cancer Res. 4:137–140. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Solomon LA, Munkarah AR, Schimp VL, et al: Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol. 101:385–389. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Burnett GT, Weathersby DC, Taylor TE and Bremner TA: Regulation of inflammation and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages. Anticancer Res. 28:2093–2099. 2008.PubMed/NCBI | |
|
Spitz GA, Furtado CM, Sola-Penna M and Zancan P: Acetylsalicylic acid and salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-phosphofructo-1-kinase structure and activity. Biochem Pharmacol. 77:46–53. 2009. View Article : Google Scholar : PubMed/NCBI |
